🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchEcnoglutide, mazdutide, and other emerging GLP-1 pipeline agents Page 3

Ecnoglutide, mazdutide, and other emerging GLP-1 pipeline agents

TrialTracker_MD Thu, Jun 4, 2026 at 9:47 AM 19 replies 418 viewsPage 3 of 4
josh_phd_bmore
Member
389
1,678
Jul 2024
Baltimore, MD
Jun 5, 2026 at 3:12 AM#11
james_edin said:
The useful move here is to separate what is established from what is widely repeated.

Saving this. It is the first explanation that did not require me to already understand it. Sending this to two other people who asked me the same thing last week.

32 7NurseKim_ATL, paul_denver, TinaHashiRN and 29 others
Reply Quote Save Share Report
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
Jun 5, 2026 at 9:45 AM#12

From the other side of the consultation, briefly. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

31 6Dr.GutHealth, amsterdam_pete, LondonLisa and 28 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Jun 5, 2026 at 4:18 PM#13
Dr.ObesityLA said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.

30 5lori_vegas, Dr.PulmRoch, maya_sedona and 27 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Jun 5, 2026 at 10:51 PM#14

The figures, for anyone assembling their own picture. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.

Last edited: Jun 5, 2026 at 11:51 PM
29 4Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 26 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 6, 2026 at 5:24 AM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Carry on.

28 3PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 25 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register